Recent Updates
Recently added Catalysts

MK-2828

Phase 1

Diabetes Mellitus, Type 2 | Small molecule | Metabolic |Merck & Company, Inc.|Last Updated: Jul 17, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment46
FDA Designations
No designations recorded
Clinical trial landscape

MK-2828 · 4 trials · 5 indications

Phase 1 4
NCT07431866A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)Healthy
COMPLETED41 Analytics
NCT07435194A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)Healthy
RECRUITING28 Analytics
NCT07348237A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)Chronic Kidney Failure
RECRUITING24 Analytics
NCT07089784Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)Diabetes Mellitus, Type 2
COMPLETED46 Analytics
PHASE1COMPLETED
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Healthy
NCT0743186641
Unlock trial analytics
PHASE1RECRUITING
A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)
Healthy
NCT0743519428
Unlock trial analytics
PHASE1RECRUITING
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
Chronic Kidney Failure
NCT0734823724
Unlock trial analytics
PHASE1COMPLETED
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
Diabetes Mellitus, Type 2
NCT0708978446
Unlock trial analytics
Study Endpoints
Primary Endpoints
Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Rosuvastatin
At designated time points (up to approximately 2 weeks)

Blood samples will be collected to determine the AUC0-inf of rosuvastatin.

Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Furosemide
At designated time points (up to approximately 2 weeks)

Blood samples will be collected to determine the AUC0-inf of furosemide.

Part 1 (Itraconazole): Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MK-2828
Predose and at designated timepoints up to approximately 288 hours (hrs) postdose

Blood samples will be collected at multiple time points to determine the AUC0-inf of MK-2828.

Part 1 (Itraconazole): Maximum Plasma Concentration (Cmax) of MK-2828
Predose and at designated timepoints up to approximately 288 hrs postdose

Blood samples will be collected at multiple time points to determine the Cmax of MK-2828.

Part 2 (Midazolam): Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Midazolam
Predose and at designated timepoints up to approximately 24hrs postdose

Blood samples will be collected at multiple time points to determine the AUC0-inf of Midazolam.

Part 2 (Midazolam): Maximum Plasma Concentration (Cmax) of Midazolam
Predose and at designated timepoints up to approximately 24hrs postdose

Blood samples will be collected at multiple time points to determine the Cmax of Midazolam.

Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of MK-2828 in Plasma
Pre dose and at designated time points up to 192 hours post dose

Blood samples will be collected to determine the AUC0-inf of MK-2828

Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of MK-2828 in Plasma
Pre dose and at designated time points up to 192 hours post dose

Blood samples will be collected to determine the AUC0-last of MK-2828

Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of MK-2828 in Plasma
Pre dose and at designated time points up to 24 hours post dose

Blood samples will be collected to determine the AUC0-24 of MK-2828

Maximum Plasma Concentration (Cmax) of MK-2828 in Plasma
Pre dose and at designated time points up to 192 hours post dose

Blood samples will be collected to determine the Cmax of MK-2828

Time of the Maximum Observed Concentration (Tmax) of MK-2828 in Plasma
Pre dose and at designated time points up to 192 hours post dose

Blood samples will be collected to determine the Tmax of MK-2828

Concentration at 24 Hours Postdose (C24) of MK-2828 in Plasma
At designated time points up to 24 hours post dose

Blood samples will be collected to determine the C24 of MK-2828

Apparent Terminal Elimination Half-life (t1/2) of MK-2828 in Plasma
Pre dose and at designated time points up to 192 hours post dose

Blood samples will be collected to determine the t1/2 of MK-2828

Apparent Total Plasma Clearance (CL/F) of MK-2828
Pre dose and at designated time points up to 192 hours post dose

Blood samples will be collected to determine the CL/F of MK-2828

Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of MK-2828 in Plasma
Pre dose and at designated time points up to 192 hours post dose

Blood samples will be collected to determine the Vz/F of MK-2828

Number of Participants Who Experience an Adverse Event (AE)
Up to approximately 42 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Number of Participants Who Discontinue Study Treatment Due to an AE
Up to approximately 28 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Secondary Endpoints
Number of Participants Who Experience an Adverse Event (AE)
Up to approximately 1 month
Number of Participants Who Discontinue Study Treatment Due to an AE
Up to approximately 2 weeks
Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Rosuvastatin
At designated time points (up to approximately 2 weeks)
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Rosuvastatin + MK-2828EXPERIMENTALParticipants receive rosuvastatin and MK-2828 orally.
Furosemide + MK-2828EXPERIMENTALParticipants receive furosemide and MK-2828 orally.
Part 1: ItraconazoleEXPERIMENTALParticipants will receive multiple oral doses of Itraconazole with a single oral dose of MK-2828.
Part 2: MidazolamEXPERIMENTALParticipants will receive multiple oral doses of MK-2828 with a single oral dose of midazolam.
Severe Renal ImpairmentEXPERIMENTALParticipants with severe renal impairment will receive a single dose of MK-2828 on Day 1
End Stage Renal Disease (ESRD) on Hemodialysis (HD)EXPERIMENTALParticipants with ESRD will receive a single dose of MK-2828 on Day 1 in each of 2 periods, with a washout of at least 14 days between doses.
Healthy Mean Matched ControlEXPERIMENTALParticipants with normal renal function will receive a single dose of MK-2828 on Day 1
MK-2828EXPERIMENTALParticipants receive daily MK-2828 for 28 days.
PlaceboPLACEBO_COMPARATORParticipants receive daily placebo for 28 days.
Interventions
NameTypeDescription
RosuvastatinDRUGOral administration
FurosemideDRUGOral administration
MK-2828DRUGOral administration
ItraconazoleDRUGAdministered orally as syrup
MidazolamDRUGAdministered orally as syrup
PlaceboDRUGPlacebo to match MK-2828 oral capsule, taken once per day for 28 days.
Unlock Study Design Details
Eligibility Criteria
Age Range24 Years to 60 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2 Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of clinically signifi...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJul 17, 2026NCT07348237primaryCompletionDate: changed
LOWJul 17, 2026NCT07348237primaryCompletionDate: changed
LOWJul 2, 2026NCT07431866Completion: 2026-06-11 → 2026-06-13
LOWJul 2, 2026NCT07431866Completion: 2026-06-11 → 2026-06-13
MEDIUMJun 22, 2026NCT07089784TRIAL_REMOVED: changed
HIGHJun 22, 2026NCT07431866Status: ACTIVE_NOT_RECRUITING → COMPLETED
MEDIUMJun 22, 2026NCT07089784TRIAL_REMOVED: changed
HIGHJun 22, 2026NCT07431866Status: ACTIVE_NOT_RECRUITING → COMPLETED
MEDIUMJun 22, 2026NCT07089784TRIAL_REMOVED: changed
LOWJun 9, 2026NCT07431866primaryCompletionDate: changed
LOWJun 9, 2026NCT07431866primaryCompletionDate: changed
LOWJun 9, 2026NCT07431866primaryCompletionDate: changed
LOWJun 9, 2026NCT07431866primaryCompletionDate: changed
LOWJun 2, 2026NCT07348237primaryCompletionDate: changed
MEDIUMJun 2, 2026NCT07431866Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWJun 2, 2026NCT07348237primaryCompletionDate: changed
MEDIUMJun 2, 2026NCT07431866Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWJun 2, 2026NCT07348237primaryCompletionDate: changed
MEDIUMJun 2, 2026NCT07431866Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWMay 26, 2026NCT07348237primaryCompletionDate: changed